![David Beadle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Beadle is a professional who has worked as a Non-Executive Director at Phico Therapeutics Ltd. since 2019.
Prior to this, he worked as a Director & Chief Business Officer at Revolo Biotherapeutics Ltd. and as a Research Analyst at UBS Ltd. Mr. Beadle completed his undergraduate degree at the University of Birmingham.
| Companies | Position | End |
|---|---|---|
Revolo Biotherapeutics Ltd.
 Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops immunologic and inflammatory medications | Director/Board Member | - |
Phico Therapeutics Ltd.
 Phico Therapeutics Ltd. BiotechnologyHealth Technology Develops novel platform technology designed to overcome antibacterial resistance | Director/Board Member | - |
UBS Ltd. (Broker)
 UBS Ltd. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
UBS Ltd. (Broker)
UBS Ltd. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
University of Birmingham
 University of Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. BiotechnologyHealth Technology Develops novel platform technology designed to overcome antibacterial resistance | Health Technology |
Revolo Biotherapeutics Ltd.
Revolo Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops immunologic and inflammatory medications | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
